Renal Devices: New Blood Revitalizes Dialysis Industry
This article was originally published in Start Up
CMS pays 33% of its budget for patients with end stage kidney disease, a group that, in terms of patient numbers, accounts for less than 1% of the Medicare population. For all this money spent, mortality rates remain high--the one year mortality rate for patients on hemodialysis stands at 24%, a survival rate that's worse than that of metastatic cancer. In an industry traditionally resistant to change, however, changes are coming, brought about by reimbursement changes and a delivery model that can't scale-up to meet a growing population, making room for new start-ups in the space.
You may also be interested in...
First Minimally Invasive Vascular Access Technology Has Potential to Revolutionize Growing Hemodialysis Market
With a projected worldwide market of over three million hemodialysis patients by 2020, TVA Medical Inc. sees a potential $1 billion+ annual market opportunity with everlinQ, a minimally invasive, catheter-based system that allows physicians to use an endovascular approach to create an arteriovenous fistula (AVF) for vascular access in chronic kidney patients who require ongoing hemodialysis.
Innovation in sensors and nanostructured materials are paving the way for new wearable artificial kidney devices, a technology with a worldwide market potential of more $26 billion.
Start-Up interviews the inventors behind Ardian, the object of one of the highest priced venture capital-backed medical device acquisitions, and between them, five other medical device companies. The team uniquely brings a perspective of applied physiology, and the integration of systems, to the goal of device innovation. In CHF Solutions, they've addressed heart failure with a device from nephrology, in Cardiac Conetps, heart failure by way of a neurological approach to sleep apnea, and in Ardian, hypertension, by studying the functioning of the kidney.